In last trading session, Lucid Diagnostics Inc (NASDAQ:LUCD) saw 0.72 million shares changing hands with its beta currently measuring 1.23. Company’s recent per share price level of $1.12 trading at -$0.02 or -1.75% at ring of the bell on the day assigns it a market valuation of $121.18M. That closing price of LUCD’s stock is at a discount of -60.71% from its 52-week high price of $1.80 and is indicating a premium of 35.71% from its 52-week low price of $0.72. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 1.2 million shares which gives us an average trading volume of 1.26 million if we extend that period to 3-months.
For Lucid Diagnostics Inc (LUCD), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.00. Splitting up the data highlights that, out of 3 analysts covering the stock, 1 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 0 suggested the stock as a Hold whereas 2 see the stock as a Buy. 0 analyst(s) advised it as an Underweight.
Lucid Diagnostics Inc (NASDAQ:LUCD) trade information
Lucid Diagnostics Inc’s shares saw a change of 28.04% in year-to-date performance and have moved -1.75% in past 5-day. Lucid Diagnostics Inc (NASDAQ:LUCD) showed a performance of -8.94% in past 30-days. Number of shares sold short was 1.66 million shares which calculate 1.38 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of 2 to the stock, which implies a rise of 44.0% to its current value. Analysts have been projecting 2 as a low price target for the stock while placing it at a high target of 2. It follows that stock’s current price would drop -78.57% in reaching the projected high whereas dropping to the targeted low would mean a loss of -78.57% for stock’s current value.
Lucid Diagnostics Inc (LUCD) estimates and forecasts
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of -54.43% during past 5 years. In 2025, company’s earnings growth rate is likely to be around 31.90% while estimates for its earnings growth in next 5 years are of 37.27%.
Lucid Diagnostics Inc (NASDAQ:LUCD)’s Major holders
Insiders are in possession of 34.54% of company’s total shares while institution are holding 9.78 percent of that, with stock having share float percentage of 14.94%. Investors also watch the number of corporate investors in a company very closely, which is 9.78% institutions for Lucid Diagnostics Inc that are currently holding shares of the company. LUMINUS MANAGEMENT LLC is the top institutional holder at LUCD for having 0.73 million shares of worth $0.6 million. And as of 2024-06-30, it was holding 1.6124 of the company’s outstanding shares.
The second largest institutional holder is VANGUARD GROUP INC, which was holding about 0.56 million shares on 2024-06-30. The number of shares represents firm’s hold over 1.2461 of outstanding shares, having a total worth of $0.46 million.
On the other hand, VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund and VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund are the top two Mutual Funds which own company’s shares. As of Mar 31, 2025 , the former fund manager was holding 612.6 shares of worth $0.69 million or 0.57% of the total outstanding shares. The later fund manager was in possession of 276.27 shares on Mar 31, 2025 , making its stake of worth around $0.31 million in the company or a holder of 0.26% of company’s stock.
